Curated News
By: NewsRamp Editorial Staff
June 25, 2026
AI-Powered Heart Tests Now Covered for LA Managed Care Patients
TLDR
- Cardio Diagnostics expands insurance coverage for its coronary heart disease tests, potentially increasing market share and revenue.
- Epi+Gen CHD evaluates three-year coronary heart disease risk, while PrecisionCHD diagnoses disease and identifies molecular drivers via noninvasive blood tests.
- Expanded coverage of noninvasive, radiation-free heart disease tests makes precision cardiovascular care more accessible to managed care populations.
- Atlas Healthcare Physicians now covers Cardio Diagnostics' blood tests that assess heart disease risk without requiring fasting or radiation.
Impact - Why it Matters
This coverage expansion matters because it brings cutting-edge, noninvasive cardiovascular diagnostics to a broader patient population, potentially enabling earlier detection and personalized treatment of coronary heart disease. For managed care members in Los Angeles and Orange counties, this means access to tests that can predict heart attack risk and guide therapy without invasive procedures or radiation. For the healthcare system, it could reduce costs by preventing heart events through precision medicine. As heart disease remains a leading cause of death, such innovations are critical to improving outcomes and making advanced care more equitable.
Summary
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, has announced a significant expansion in patient access to its innovative blood tests. Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will now provide coverage for the company’s Epi+Gen CHD™ and PrecisionCHD™ tests for eligible members with prior authorization. This development, reported via NEWMEDIAWIRE, marks a pivotal step in bringing advanced cardiovascular diagnostics to community healthcare networks. The tests are designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning, leveraging the company's proprietary AI-driven Integrated Genetic-Epigenetic Engine.
The Epi+Gen CHD™ test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD™ helps diagnose coronary heart disease and identify its underlying molecular drivers. Both are noninvasive, blood-based diagnostics that do not require fasting or radiation exposure, making them more accessible and patient-friendly. This coverage expansion underscores Cardio Diagnostics' mission to make cardiovascular disease prevention, detection, and management more personalized and precise. By integrating these tests into managed care populations, the company aims to improve outcomes for patients who might otherwise lack access to such advanced diagnostics.
Cardio Diagnostics, headquartered in Chicago, continues to innovate in the field of precision medicine. The company’s Core Technology, an AI-driven engine, enables the development of clinical tests that can potentially transform how cardiovascular disease is managed. For more details, the full press release can be accessed at https://nnw.fm/EFQen. This news is particularly relevant given the growing prevalence of heart disease and the need for early, accurate detection methods that can be deployed widely in community settings.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, AI-Powered Heart Tests Now Covered for LA Managed Care Patients
